Use of recombinant activated factor VII for massive postpartum hemorrhage

References

• McLintock C. Postpartum haemorrhage. Thromb Res 2005; 115(Suppl 1)65–8
   PubMed Web of Science ®Google Scholar
• Mazouni C, Gorincour G, Juhan V, Bretelle F. Placenta accreta: a review of current advances in prenatal diagnosis. Placenta. 2006 July;28(7):599–603.
   PubMed Web of Science ®Google Scholar
• Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Semin Hematol 2001; 38(4 Suppl 12)43–7
   PubMed Web of Science ®Google Scholar
• Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007; 83(2)707–14
   PubMed Web of Science ®Google Scholar
• Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004; 104(13)3858–64
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005; 93(6)1027–35
   PubMed Web of Science ®Google Scholar
• Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol. 2003; 101(6)1174–6
   PubMed Web of Science ®Google Scholar
• Lim Y, Loo CC, Chia V, Fun W. Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. Int J Gynaecol Obstet. 2004; 87(2)178–9
   PubMed Web of Science ®Google Scholar
• Moscardo F, Perez F, de la Rubia J, Balerdi B, Lorenzo JI, Senent ML, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001; 114(1)174–6
   PubMed Web of Science ®Google Scholar
• Shamsi TS, Hossain N, Soomro N, Hasan JA, Noorani M, Kazi S, et al. Use of recombinant factor VIIa for massive postpartum haemhorrage: case series and review of literature. J Pak Med Assoc. 2005; 55(11)512–5
   PubMedGoogle Scholar
• Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet. 2003; 268(4)266–7
   PubMedGoogle Scholar
• Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening postpartum haemorrhage. Br J Anaesth. 2005; 94(5)592–5
   PubMed Web of Science ®Google Scholar
• Ronsmans C. Maternal mortality: who, when, where, and why. Lancet. 2006; 368(9542)1189–1200
   PubMed Web of Science ®Google Scholar
• AbouZahr C, Wardlaw T, Stanton C, Hill K. Maternal mortality. World Health Stat Q 1996; 49(2)77–87
   PubMedGoogle Scholar
• Mousa H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. (1):CD003249; 2007.
   Google Scholar
• Sobieszczyk S, Breborowicz GH, Platicanov V, Tanchev S, Kessler CM. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand. 2006; 85(10)1239–47
   PubMed Web of Science ®Google Scholar
• Scarpelini S, Rizoli S. Recombinant factor VIIa and the surgical patient. Curr Opin Crit Care. 2006; 12(4)351–6
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective. Crit Care. 2006; 10(4)R120
   PubMed Web of Science ®Google Scholar
• Mousa HA, Walkinshaw S. Major postpartum haemorrhage. Curr Opin Obstet Gynecol. 2001; 13(6)595–603
   PubMed Web of Science ®Google Scholar
• Smith J, Mousa HA. Peripartum hysterectomy for primary postpartum haemorrhage: incidence and maternal morbidity. J Obstet Gynaecol. 2007; 27(1)44–7
   PubMedGoogle Scholar
• Karalapillai D, Popham P. Recombinant factor VIIa in massive postpartum haemorrhage. Int J Obstet Anesth. 2007; 16(1)29–34
   PubMed Web of Science ®Google Scholar
• Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004; 2(6)899–909
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003; 14(8)713–7
   PubMed Web of Science ®Google Scholar
• Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth. 2007; 16(1)40–9
   PubMed Web of Science ®Google Scholar